Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
214
resultados
Última actualización
12/03/2026 [06:53:00]
Resultados 75 a 100 de 214
Resumen de: WO2026047271A1
The present invention relates to a nanoparticle system comprising a metal selected from silver and gold, coated with polyethylene glycol (PEG) and functionalised with a polyphenol organic acid selected from caffeic acid, gallic acid and ferulic acid. The present invention also relates to a method for manufacturing said nanoparticle system and to the therapeutic and cosmetic use of said nanoparticle system.
Resumen de: WO2026045748A1
The present invention relates to the use of tRNA in promoting the protein-coding ability of mRNA. The expression level of a target protein is improved by means of overexpressing tRNA, and a codon corresponding to the tRNA can promote or improve the stability of the mRNA. Further provided is a new tRNA+mRNA immunopotentiating vaccine. By means of introducing one or more tRNA molecules, the antigen protein encoding ability of an mRNA vaccine is enhanced, thereby eliciting stronger humoral and cellular immune responses in vivo. Further provided is a recombinant cell for producing an antibody. The recombinant cell overexpresses tRNA capable of increasing the expression level of the antibody, and the tRNA comprises a tRNA isodecoder family. Further provided is a recombinant cell for producing or packaging recombinant AAV, wherein the recombinant cell overexpresses tRNA capable of improving the AAV packaging efficiency.
Resumen de: WO2026050738A1
The present disclosure provides polymeric nanoparticles including block copolymers which possess reactive oxygen species (ROS) quenching units to reduce oxidative stress to prevent neurodegeneration and which can also be used to encapsulate an active pharmaceutical ingredient, a diagnostic marker, or a combination thereof in a pharmaceutical composition. The polymeric nanoparticles of the present disclosure are designed to release ROS quenchers, the active pharmaceutical ingredient, the diagnostic marker, or the combination thereof upon exposure to a pH below about 6.5, exposure to a reactive oxygen species, or a combination thereof. Methods of diagnosing or treating radiotherapy-induced brain injuries in a patient are also described.
Resumen de: WO2026050750A1
The present invention is related to compositions and methods for modifying the hepatitis B virus (HB V) genome using CRISPR gene editing technology to treat a subject suffering from HBV. The present invention is also related to compositions of modified HB V genomes.
Resumen de: WO2026050148A1
Non-viral gene therapy treatments have a number of advantages over viral vectors including typical non-antigenicity, low manufacturing cost, simplicity, and efficiency of delivering genetic cargo into the cytoplasm. The potency of non-viral gene therapy systems can be enhanced by providing them with means to more efficiently transport the delivered DNA from the cytoplasm to the nucleus. Provided herein, at least in part, are means of enhancing potency of non-viral gene therapies by including novel nuclear translocation enhancing sequences and compositions that can result in optimized nuclear translocation as well as related compositions and methods.
Resumen de: WO2026050140A1
A modified nanoparticle nanocarrier system for delivering one or more active ingredients into a skin that can slowly release the active ingredients is provided. The modified nanoparticle nanocarrier system comprises a dendrimer, a linker and a peptide, wherein the dendrimer is first coated with the linker to form a dendrimer-linker conjugate, and the dendrimer-linker conjugate is then coupled to a peptide to form a dendrimer-linker-peptide conjugate. Subsequently, the dendrimer-linker-peptide conjugate is loaded with one or more active ingredients and mixed with a topical base to form a homogenized product to be applied onto the skin.
Resumen de: WO2026049650A1
The invention relates to the fields of colloidal chemistry and medicinal chemistry. A surfactant containing branched hydrophobic chains with amino acid residues at the branching point is characterized by general formula (I), where R1-A-R2 represents an amino acid residue; k can be equal to 1, 2 or 3; l can be equal to 3, 4, 5, 6 or 7; the amino acid residue has an L configuration; R1 and R2 are the same or different residues from the list shown; m is an integer from 4 to 13. New compounds are obtained which provide for better binding of molecules inside lipid nanoparticles (LNPs), as well as more uniform packing of molecules inside LNPs, without the formation of ordered phases such as a lamellar phase.
Resumen de: WO2026049467A1
The present invention relates to a composition for alleviating or treating hair loss in which a hair loss drug is loaded in lipid nanoparticles. The lipid nanoparticles contain 0.30 mol% or more of a hydrophobic drug such as finasteride or dutasteride relative to the lipid nanoparticles and are loaded with the hydrophobic drug at an encapsulation rate of 90.0% or more, and thus have the advantage of being able to maintain water dispersibility for a long period of time while increasing transdermal delivery. Therefore, the present invention can more effectively alleviate symptoms of male pattern hair loss on the scalp where localized hair loss or thinning of hair occurs.
Resumen de: WO2026048880A1
The present invention provides a nanoparticle with which it is possible, safely, efficiently, and stably over a long period of time, to introduce siRNA used for RNA interference into an intervertebral disk cell. This nanoparticle is used for prevention or treatment of intervertebral disk degeneration, and has a biodegradable hydrogel and a ribonucleic acid molecule that is retained by a particle of the biodegradable hydrogel and that selectively inhibits an activity of a mammalian target of rapamycin (mTOR) complex.
Resumen de: WO2026047519A1
Described herein are pharmaceutical compositions and methods of their use for the treatment of cancer. The pharmaceutical compositions comprise a first anticancer drug formulated as nanoparticles or microparticles, the nanoparticles or microparticles uniformly dispersed in the injectable hydrogel polymer matrix formulation. This matrix comprises an anionic polymer and an inverse thermal gelling polymer, which transitions from a liquid to a gel state at specific temperatures and demonstrates shear-thinning properties to facilitate injection and gel reformation. The pharmaceutical compositions are administered intratumorally into solid tumors to treat cancer in a subject requiring such treatment. The method may additionally include systemic administration of a therapeutically effective amount of a second anticancer drug.
Resumen de: WO2026046237A1
Provided is a lung-targeting lipid compound, specifically relating to a compound as shown in formula (I), or an isotopic variant, tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt thereof. Also provided are a nanoparticle pharmaceutical composition comprising the compound, and a use of the compound and the composition thereof in lung targeted delivery of nucleic acids.
Resumen de: WO2026045510A1
Provided are a metal-organic framework nanomaterial, a preparation method therefor, and a use thereof, belonging to the technical field of bionanomaterials, and resolving the technical problem of inhibiting atherosclerosis using biomimetic metal-organic framework nanoenzymes. The solution is: the components of the of the metal-organic framework nanomaterial and the ratio thereof are: metal ions Ce4+ and a ligand fumaric acid in a molar ratio of 1:5. The preparation method therefor is: measuring an FA regulator and water to prepare a mixed solution, then adding fumaric acid and cerium ammonium nitrate dropwise into the mixed solution, stirring at room temperature, centrifuging, repeatedly washing alternately with water and ethanol, and finally drying overnight in a vacuum oven. A simple, efficient and convenient method for synthesizing the metal-organic framework nanomaterial is provided. The synthesized metal-organic framework nanomaterial has excellent CEH-like enzyme activity and intrinsic antioxidant activity, and can be used to increase lipid efflux and reduce lipid uptake, and decrease ox-LDL-induced foam cell formation, thereby alleviating atherosclerosis.
Resumen de: US20260062716A1
The present disclosure relates generally to lipid nanoparticle compositions comprising a nucleic acid, an ionizable polymer, a cationic lipid, a phospholipid, a sterol, and a PEG-lipid. Further, the present disclosure relates generally to methods of treating or preventing a disease, comprising administering to a subject in need thereof a lipid nanoparticle composition described herein.
Resumen de: US20260062697A1
The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide a desired translational regulatory activity to the mRNA.
Resumen de: WO2026050351A1
LNPs can penetrate uterine mucosa to deliver therapeutic or prophylactic agents such as functional nucleic acids to the endometrium. Targeting of the LNPs using ligands expressed at particular times in an endometrial cycle ensures that the LNPs penetrate and release the mRNA primarily to the tissue associated with the peak time period for implantation, thereby providing a means to address infertility, as well as for treatment of other disorders such as cancer.
Resumen de: WO2026046962A1
The present disclosure provides pharmaceutical compositions comprising nanoparticles, wherein the nanoparticles each comprise a micelle comprising an amphiphilic polymer, and at least one peptide. The present disclosure further provides methods of treating an autoimmune disease (e.g., multiple sclerosis, type 1 diabetes) in a human subject in need thereof comprising administering the pharmaceutical compositions provided herein.
Resumen de: WO2026047192A1
The present invention generally relates to the field of ionizable (also termed cationic) lipids, and in particular provides a novel type of such lipids as represented by formula (I). The present invention further provides methods for making such lipids as well as uses thereof, in particular in the preparation of nanoparticle compositions, more in particular nanoparticle compositions comprising nucleic acids. It further provides vaccine formulations comprising nanoparticle compositions based on the ionizable lipid disclosed herein.
Resumen de: WO2026047418A1
Extracellular vesicles (PDEVs) for reaching the blood-brain barrier characterized by: be obtained from oranges from organic farming and to contain within the lipid membrane a ratio between the concentration of Phosphatidylethanolamine (PE) and the concentration of Phosphatidic Acid (PA) between 8 and 15.
Resumen de: US20260061071A1
Disclosed is a multi-functional nanoparticle delivery system comprising a biodegradable core of poly(lactic-co-glycolic acid) (PLGA) or calcium phosphate (CaP), encapsulating a nicotinamide adenine dinucleotide (NAD+) precursor and a sirtuin activator. Surrounding the core is a liposomal or polymeric layer containing one or more senolytic agents, and an outer layer of magnetic iron oxide nanoparticles for targeted delivery, external manipulation, and imaging. In some embodiments, the nanoparticle surface is functionalized for conjugation with autologous mesenchymal stem cells to enhance homing and regenerative potential. The system is pH-responsive, releasing its payload in acidic microenvironments typical of senescent or diseased cells, while remaining stable at physiological pH. This integrated design supports NAD+ restoration, sirtuin activation, senescent cell clearance, and tissue regeneration. Applications include treatment of age-related diseases, regenerative medicine, cardiovascular and neurodegenerative disorders, and cosmetic skin rejuvenation.
Resumen de: US20260061082A1
PSMA targeted metal chelate nanodrugs, methods of making these nanodrugs and methods of using them for radiodiagnosis and radiotherapy are provided.
Resumen de: US20260061070A1
The present disclosure presents nanoparticle compositions for use in the treatment, prevention, or imaging of a disease (e.g., cancer), methods of treating, preventing, or imaging a disease in a subject in need thereof with the nanoparticle compositions, and methods of preparing the nanoparticle compositions of the disclosure. The nanoparticle compositions can include a magnetic nanoparticle ferric chloride, ferrous chloride, or a combination thereof, and a dextran coating functionalized with one or more amine groups.
Resumen de: US20260060936A1
A composition containing a mixture of oligomers or co-oligomers obtained by exposing an indolium-based monomer, optionally together with an additional monomer selected from dopamine, L-dopa, norepinephrine, serotonin, and a mixture thereof, to a basic buffer. The composition may further contain a hydrophobic substance such as a drug or dietary supplement, stabilized by the oligomers above.
Resumen de: US20260061018A1
A method for treating a gastrointestinal condition includes preparing an aqueous extract of bioactive compound by adding dried green tea material to hot water and filtering the aqueous extract; adding a solution of an iron-containing compound to the filtered aqueous extract to form a complex or chelate of the bioactive compounds with iron; and drying the solution at a temperature between 80 to 150 degrees Fahrenheit to obtain a fine granular or powdered state.
Resumen de: US20260061036A1
Various peroxidases are useful in treating subjects suffering from diseases associated with buildup of bisretinoids. The disclosed peroxidases may also be useful in activating prodrugs. The disclosed peroxidases may be administered as mature proteins or as coding sequences, in the form of expression vectors (as one example viral vectors) or lipid nanoparticles.
Nº publicación: US20260061028A1 05/03/2026
Solicitante:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US]
President and Fellows of Harvard College
Resumen de: US20260061028A1
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).
BOPI
Sede Electrónica
